These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 37602635

  • 21. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW.
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [Abstract] [Full Text] [Related]

  • 22. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J, Mei H, Su NY, Sun WJ, Zhang DK, Fan LL, He P, Pan J, Wang XW, Zou PY, Liu YX, Guo Y, Lan CH.
    Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 26. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis.
    Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ.
    World J Gastroenterol; 2014 Oct 28; 20(40):14973-85. PubMed ID: 25356059
    [Abstract] [Full Text] [Related]

  • 27. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, Xu M, Zhang ZY, Li SL, Wang QY, Su CX, Chen Y, Chen J, Lin Y, Li PY.
    J Gastroenterol; 2023 Dec 28; 58(12):1167-1177. PubMed ID: 37777987
    [Abstract] [Full Text] [Related]

  • 28. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C, Buranathawornsom A.
    J Gastroenterol Hepatol; 2021 Dec 28; 36(12):3308-3313. PubMed ID: 34622504
    [Abstract] [Full Text] [Related]

  • 29. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z, Chen X, Sun DJ, Zhao WW, Kou L, Zheng WW, Hao JR, Gao FY.
    Medicine (Baltimore); 2024 Mar 08; 103(10):e37476. PubMed ID: 38457567
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL, Wang JH, He XJ, Zhu YB, Lu LJ, Wang YJ, Wang ZW, Gao JG, Xu CF, Ma H, Luan SM, Li L, Chen Y.
    Am J Gastroenterol; 2024 Apr 01; 119(4):655-661. PubMed ID: 37975609
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
    Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z.
    Helicobacter; 2021 Aug 01; 26(4):e12816. PubMed ID: 34002433
    [Abstract] [Full Text] [Related]

  • 39. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL.
    Aliment Pharmacol Ther; 2022 Aug 01; 56(3):436-449. PubMed ID: 35665947
    [Abstract] [Full Text] [Related]

  • 40. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T.
    Helicobacter; 2021 Apr 01; 26(2):e12788. PubMed ID: 33580612
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.